Company intelligence / Profile preview

Scios Inc.

Sunnyvale, California, United Statesscios.ai ↗

Ownership: Private
Development stage: Commercial

Overview

Scios developed Natrecor (nesiritide), a genetically engineered protein approved in 2001 for acute heart failure. The drug generated approximately $100-107 million in sales in its first full year on the market. The company was also developing SCIO-469, a p38 kinase inhibitor for arthritis that was in early human testing.

Therapeutic areas: OncologyImmunologyCardiovascular
Modalities: Recombinant proteinsSmall moleculesKinase inhibitors
Industry: Biotech

Partnerships

GlaxoSmithKline

Beyond the preview

Go deeper on Scios Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scios Inc..

Explore the full profile